Marker Total Current Liabilities from 2010 to 2025
| MRKR Stock | USD 1.37 0.21 18.10% |
Total Current Liabilities | First Reported 2000-03-31 | Previous Quarter 2 M | Current Value 3.5 M | Quarterly Volatility 4.9 M |
Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 12.9 K or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 15.99, Dividend Yield of 0.0 or PTB Ratio of 3.26. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.
Marker | Total Current Liabilities |
Latest Marker Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Marker Therapeutics over the last few years. Total Current Liabilities is an item on Marker Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Marker Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Marker Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marker Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Marker Total Current Liabilities Regression Statistics
| Arithmetic Mean | 5,893,801 | |
| Geometric Mean | 3,595,991 | |
| Coefficient Of Variation | 114.64 | |
| Mean Deviation | 4,308,369 | |
| Median | 3,800,572 | |
| Standard Deviation | 6,756,499 | |
| Sample Variance | 45.7T | |
| Range | 27.8M | |
| R-Value | (0) | |
| Mean Square Error | 48.9T | |
| R-Squared | 0.0000013 | |
| Significance | 1.00 | |
| Slope | (1,616) | |
| Total Sum of Squares | 684.8T |
Marker Total Current Liabilities History
About Marker Therapeutics Financial Statements
Marker Therapeutics shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Marker Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marker Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 3.5 M | 4.6 M |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.